DPP4 and type 2 diabetes mellitus: Clinical studies have revealed that the long-term administration of DPP4 inhibitors improves the postprandial atherogenic levels of TG-rich lipoprotein and/or endothelial dysfunction in patients with type 2 diabetes and healthy volunteers (9–11).